A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
NCT05816382
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
RECRUITING
Status
500
Enrollment
INDUSTRY
Sponsor class
Conditions
Narcolepsy Type 1
Interventions
DRUG:
TAK-861
Sponsor
Takeda